Floatz logo

(+)-VINCRISTINE

PD-1

Anhui Provincial HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the PD-1 cohort.

Asset / SponsorPhaseRating
f520
Shandong New Time Pharmaceutical Co., LTD
Phase 2CCC
Ruxoprubart
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2CCC
Iparomlimab
Anhui Provincial Hospital
Phase 2CCC
LENVATINIB
The First Affiliated Hospital with Nanjing Medical University
Phase 2CCC
Dasatinib
The Affiliated Hospital of Qingdao University
Phase 2CCC

View all 14 →

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →